WO2022229705A1 - Uso de recambio plasmático terapéutico y recambio plasmático de bajo volumen para el tratamiento de un deterioro cognitivo - Google Patents
Uso de recambio plasmático terapéutico y recambio plasmático de bajo volumen para el tratamiento de un deterioro cognitivo Download PDFInfo
- Publication number
- WO2022229705A1 WO2022229705A1 PCT/IB2022/000246 IB2022000246W WO2022229705A1 WO 2022229705 A1 WO2022229705 A1 WO 2022229705A1 IB 2022000246 W IB2022000246 W IB 2022000246W WO 2022229705 A1 WO2022229705 A1 WO 2022229705A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lvpe
- treatment
- patient
- composition
- tpe
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 94
- 208000010877 cognitive disease Diseases 0.000 title claims abstract description 36
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 21
- 208000028698 Cognitive impairment Diseases 0.000 title claims abstract description 15
- 230000006996 mental state Effects 0.000 claims abstract description 6
- 102000008100 Human Serum Albumin Human genes 0.000 claims abstract description 5
- 108091006905 Human Serum Albumin Proteins 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims abstract 16
- 102000009027 Albumins Human genes 0.000 claims description 19
- 108010088751 Albumins Proteins 0.000 claims description 19
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 18
- 210000004369 blood Anatomy 0.000 claims description 14
- 239000008280 blood Substances 0.000 claims description 14
- 238000012360 testing method Methods 0.000 claims description 14
- 208000024827 Alzheimer disease Diseases 0.000 claims description 10
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 7
- 201000002832 Lewy body dementia Diseases 0.000 claims description 7
- 208000018737 Parkinson disease Diseases 0.000 claims description 7
- 238000011269 treatment regimen Methods 0.000 claims description 7
- 238000006467 substitution reaction Methods 0.000 claims description 6
- 239000003814 drug Substances 0.000 description 62
- 229940079593 drug Drugs 0.000 description 61
- 238000000034 method Methods 0.000 description 35
- 102000001554 Hemoglobins Human genes 0.000 description 16
- 108010054147 Hemoglobins Proteins 0.000 description 16
- 230000000295 complement effect Effects 0.000 description 16
- 239000012472 biological sample Substances 0.000 description 15
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 14
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 14
- 210000003743 erythrocyte Anatomy 0.000 description 14
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 14
- 229940099472 immunoglobulin a Drugs 0.000 description 14
- 229940027941 immunoglobulin g Drugs 0.000 description 14
- 108060003951 Immunoglobulin Proteins 0.000 description 11
- 238000011156 evaluation Methods 0.000 description 11
- 210000002216 heart Anatomy 0.000 description 11
- 102000018358 immunoglobulin Human genes 0.000 description 11
- 210000004185 liver Anatomy 0.000 description 11
- 230000000474 nursing effect Effects 0.000 description 11
- 230000015271 coagulation Effects 0.000 description 10
- 238000005345 coagulation Methods 0.000 description 10
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 9
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 9
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 9
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 9
- 239000011575 calcium Substances 0.000 description 9
- 229910052791 calcium Inorganic materials 0.000 description 9
- 239000011777 magnesium Substances 0.000 description 9
- 229910052749 magnesium Inorganic materials 0.000 description 9
- 239000011591 potassium Substances 0.000 description 9
- 229910052700 potassium Inorganic materials 0.000 description 9
- 239000011734 sodium Substances 0.000 description 9
- 229910052708 sodium Inorganic materials 0.000 description 9
- 230000002411 adverse Effects 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 238000002617 apheresis Methods 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 8
- 238000002595 magnetic resonance imaging Methods 0.000 description 8
- 239000001301 oxygen Substances 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 7
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 7
- 108010082126 Alanine transaminase Proteins 0.000 description 7
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 7
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 7
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 7
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 102000006395 Globulins Human genes 0.000 description 7
- 108010044091 Globulins Proteins 0.000 description 7
- 241000725303 Human immunodeficiency virus Species 0.000 description 7
- 108010094028 Prothrombin Proteins 0.000 description 7
- 102100027378 Prothrombin Human genes 0.000 description 7
- 108010000499 Thromboplastin Proteins 0.000 description 7
- 102000002262 Thromboplastin Human genes 0.000 description 7
- 210000003651 basophil Anatomy 0.000 description 7
- 238000009534 blood test Methods 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 7
- 229940109239 creatinine Drugs 0.000 description 7
- 210000003979 eosinophil Anatomy 0.000 description 7
- 238000005534 hematocrit Methods 0.000 description 7
- 210000000265 leukocyte Anatomy 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 230000003557 neuropsychological effect Effects 0.000 description 7
- 210000000440 neutrophil Anatomy 0.000 description 7
- 229940039716 prothrombin Drugs 0.000 description 7
- 238000004062 sedimentation Methods 0.000 description 7
- 208000025721 COVID-19 Diseases 0.000 description 6
- 108010049003 Fibrinogen Proteins 0.000 description 6
- 102000008946 Fibrinogen Human genes 0.000 description 6
- 241000711549 Hepacivirus C Species 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 238000004820 blood count Methods 0.000 description 6
- 210000001772 blood platelet Anatomy 0.000 description 6
- 239000004202 carbamide Substances 0.000 description 6
- 230000035487 diastolic blood pressure Effects 0.000 description 6
- 229940012952 fibrinogen Drugs 0.000 description 6
- 210000001616 monocyte Anatomy 0.000 description 6
- 230000037081 physical activity Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000002106 pulse oximetry Methods 0.000 description 6
- 230000036387 respiratory rate Effects 0.000 description 6
- 230000035488 systolic blood pressure Effects 0.000 description 6
- 206010012289 Dementia Diseases 0.000 description 5
- 230000001149 cognitive effect Effects 0.000 description 5
- 230000000926 neurological effect Effects 0.000 description 5
- 239000013049 sediment Substances 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 4
- HFSHGXIPMHQUFT-UHFFFAOYSA-N 3,8-dihydroxy-2-(hydroxymethyl)-7-methylnon-1-en-4-one Chemical compound CC(O)C(C)CCC(=O)C(O)C(=C)CO HFSHGXIPMHQUFT-UHFFFAOYSA-N 0.000 description 4
- 206010002383 Angina Pectoris Diseases 0.000 description 4
- 206010019280 Heart failures Diseases 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 229940092232 albutein Drugs 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 229940127219 anticoagulant drug Drugs 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 229940086870 plasbumin Drugs 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 206010003694 Atrophy Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 230000003208 anti-thyroid effect Effects 0.000 description 3
- 229940043671 antithyroid preparations Drugs 0.000 description 3
- 230000037444 atrophy Effects 0.000 description 3
- 239000000306 component Substances 0.000 description 3
- 238000013480 data collection Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 238000002616 plasmapheresis Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000001685 thyroid gland Anatomy 0.000 description 3
- 241001678559 COVID-19 virus Species 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 102000008857 Ferritin Human genes 0.000 description 2
- 108050000784 Ferritin Proteins 0.000 description 2
- 238000008416 Ferritin Methods 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 206010042434 Sudden death Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 208000037849 arterial hypertension Diseases 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 208000014951 hematologic disease Diseases 0.000 description 2
- 208000018706 hematopoietic system disease Diseases 0.000 description 2
- 208000031169 hemorrhagic disease Diseases 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 108010060159 Apolipoprotein E4 Proteins 0.000 description 1
- 229920000818 Catalin Polymers 0.000 description 1
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 1
- 206010021137 Hypovolaemia Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- OKPNYGAWTYOBFZ-UHFFFAOYSA-N Pirenoxine Chemical compound C12=NC3=CC=CC=C3OC2=CC(=O)C2=C1C(=O)C=C(C(=O)O)N2 OKPNYGAWTYOBFZ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- XFQYJNINHLZMIU-UHFFFAOYSA-N cataline Natural products CN1CC(O)C2=CC(OC)=C(OC)C3=C2C1CC1=C3C=C(OC)C(OC)=C1 XFQYJNINHLZMIU-UHFFFAOYSA-N 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000009760 functional impairment Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 238000010984 neurological examination Methods 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 208000023366 superficial siderosis Diseases 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000003478 temporal lobe Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/342—Adding solutions to the blood, e.g. substitution solutions
- A61M1/3455—Substitution fluids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3496—Plasmapheresis; Leucopheresis; Lymphopheresis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3693—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits using separation based on different densities of components, e.g. centrifuging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Definitions
- the present invention relates to the medical sector, in particular to the use of a therapy that combines therapeutic plasma exchange (TPE) and low volume plasma exchange (LVPE) for the treatment of cognitive impairment, in which the plasma is replaced with a solution comprising albumin.
- TPE therapeutic plasma exchange
- LVPE low volume plasma exchange
- LBD and PD are well-known diseases.
- the DCL is a concept recently proposed by scientists.
- MCI or mild neurocognitive disorder is an intermediate state (Petersen, RC, Lopez, O, Armstrong, MJ. (2016) Neurology; 90(3): 126-135) between normal aging and dementia. This state can progress to dementia, mainly in the form of Alzheimer's disease (Lopez, OL (2013) Continuum (Minneap Minn);19 (Dementia): 411-424).
- MCI had been defined with a primary focus on amnesia, but a broader definition covering impairment in a single non-amnestic domain or multiple cognitive domains with or without memory deficits has subsequently been included.
- the annual rate of progression to dementia is approximately 5%. to 17% (Ganguli, M, et al., (2013) Neurology; 80(23): 2112-2120).
- Some established biomarkers associated with progression from MCI to Alzheimer's disease are a positive positron emission tomography (PET) scan for amyloid, apolipoprotein E4 genotype, abnormal cerebrospinal fluid (CSF) tau levels, a Positive PEI scan due to tau deposition in the lateral temporal lobe (Cheng, YW, et al., (2017) Neuropsychiatr Dis Treat; 13:491-498).
- PET positron emission tomography
- CSF cerebrospinal fluid
- albumin as a replacement fluid by combining TPE and LVPE helps prevent or delay cognitive decline.
- the LVPE treatment regimen requires smaller volumes than traditional therapeutic plasma exchange, a shorter duration time, and a single venipuncture, which decreases patient discomfort and reduces adverse effects of treatment.
- the present invention relates to the use of human albumin in a concentration between 5% (w/v) and 0.25% (w/v) for the treatment of a cognitive impairment in a patient who needs it, in wherein said treatment comprises a combination of conventional therapeutic plasma exchange (TPE) and low volume plasma exchange (LVPE), and wherein said patient has a Mini Mental State Examination (MMSE) greater than or equal to fifteen.
- TPE conventional therapeutic plasma exchange
- LVPE low volume plasma exchange
- MMSE Mini Mental State Examination
- the term "Mini Mental State Test (MMSE)” refers to a score used to assess cognitive impairment in patients, track changes in cognitive functioning over over time and frequently to assess the effects of therapeutic agents on cognitive function (Folstein MF, et al., (1975) J Psychiatr Res.; 12:189-98).
- MMSE is the most commonly administered psychometric screening assessment of cognitive functioning.
- LVPE low volume plasma exchange
- each round of LVPE involves automated plasma exchange using a single venipuncture.
- the device may include an inlet port for receiving whole blood from a patient, means for separating plasma from cellular blood components, and means for returning cellular blood components through the inlet port from the blood. which the blood cell components had exited the device and an exit port through which the plasma exits the device.
- the means for separating the plasma from the cellular components of the blood is a means of centrifugation (ie, a centrifuge). More preferably, the means for separating the plasma from the cellular components of the blood is a filter media (ie, a filter such as is used in double filtration plasma exchange).
- the treatment regimen comprises administering to the patient three or more x ywaves of LVPE, four or more rounds of LVPE, five or more rounds of LVPE, six or more rounds of LVPE, seven or more rounds of LVPE, eight or more rounds of LVPE, nine or more rounds of LVPE, or ten or more rounds of LVPE, eleven or more rounds of LVPE, or twelve or more rounds of LVPE.
- each subsequent round of LVPE is carried out 10-45 days after the previous round.
- each subsequent round of LVPE is carried out 15-35 days after the previous round, plus preferably, it is carried out 30 days after the previous round.
- said LVPE is carried out with a frequency of 1 LVPE per month.
- said monthly LVPE is carried out for at least 12 months.
- said second stage of LVPE is carried out chronically whenever the patient shows a response.
- between 20 g and 50 g of albumin can be used for substitution in each round of LVPE, preferably 40 g of albumin in each round of LVPE.
- the plasma is replaced by albumin at a concentration between 18% (w/v) and 25% (w/v), preferably 20% (w/v).
- previous rounds of conventional therapeutic plasma exchange can be carried out before the LVPE treatment regimen.
- a TPE regimen can be performed at a frequency of 1 TPE per week, more preferably for at least 6 weeks.
- TPE refers to a plasma exchange in which 2,000 to 3,000 mL of plasma from the patient with the same volume of replacement fluid.
- between 100 and 150 g of albumin can be used for substitution in each round of TPE.
- the plasma is replaced by albumin at a concentration between 4% (w/v) and 6% (w/v). preferably 5% (w/v).
- said cognitive impairment is selected from the list comprising Alzheimer's disease (AD). Lewy body dementia (LBD). Parkinson's disease (PD) and mild cognitive impairment (MCI), preferably said cognitive impairment is selected from Parkinson's disease Alzheimer's (AD) and mild cognitive impairment (MCI), more preferably said cognitive impairment is mild cognitive impairment (MCI).
- AD Alzheimer's disease
- LBD Lewy body dementia
- PD Parkinson's disease
- MCI mild cognitive impairment
- said cognitive impairment is selected from Parkinson's disease Alzheimer's (AD) and mild cognitive impairment (MCI), more preferably said cognitive impairment is mild cognitive impairment (MCI).
- the patient in need of the treatment of the present invention must meet the following eligibility criteria:
- MRI Magnetic resonance imaging
- Class III Marked limitation of physical activity. Comfortable at rest. Less than usual physical activity causes fatigue, palpitations, dyspnea, or anginal pain.
- Class IV Unable to perform any physical activity without discomfort. Presence of symptoms of angina or heart failure even at rest.
- COPD chronic obstructive pulmonary disease
- the reason for this medical care protocol is to guarantee the best care and treatment for patients who are candidates for the AMBAR treatment.
- the AMBAR treatment consists of two periods of therapeutic apheresis with the following recommendation from the Treatment Supervision Committee (CST):
- TPE weekly therapeutic plasma replacement
- LVPE low-volume plasma exchange
- the medical assistance protocol is divided into four phases: selection phase, prescription phase, application phase and follow-up phase.
- the objective of the selection phase is to evaluate all the available medical information of the patient and, where appropriate, request more information, in order to assess the suitability of the patient in the next phase, the prescription phase.
- the selection phase includes a first Neurology/Internal Medicine visit, and different complementary visits.
- a candidate patient for AMBAR treatment must meet the eligibility criteria described below. Eligibility criteria must be evaluated during the first visit of Neurology/Internal Medicine complemented with the necessary analysis to make a decision in the second visit of Neurology/Internal Medicine, on whether or not said candidate patient is eligible for the AMBAR treatment.
- the evaluation of the criteria is carried out by both the neurologist and the internist, each one being responsible for fulfilling the criteria (the person responsible for fulfilling each criterion is indicated in parentheses). When deciding whether the patient is eligible or not, both professionals must give their consent.
- MMSE Mini Mental State Test
- MRI Magnetic resonance imaging
- Class III Marked limitation of physical activity. Comfortable at rest. Less than usual physical activity causes fatigue, palpitations, dyspnea, or anginal pain.
- Class IV Unable to perform any physical activity without discomfort. Presence of symptoms of angina or heart failure even at rest. - Absence of uncontrolled arterial hypertension. Treatment with beta blockers that determine a heart rate ⁇ 60 bpm (Internal Medicine).
- COPD chronic obstructive pulmonary disease
- the prerequisites for the visit are that the patient is discharged by administration with the subsequent assignment of a unique AMBAR code.
- the signature of the general consent for the protection and transfer of personal data will also be obtained.
- patients Given the current situation or pandemic, patients must have a negative PCR for COVID-19 in order to participate and attend the different visits required by the AMBAR treatment in person. It is also convenient to ask if the patient has been vaccinated against SARS-COV-2 or not.
- AMBAR general informed consent, consent to obtain biological samples for future research and consent to obtain genetic samples.
- Complementary visits are intended to obtain additional information to complete the first Neurology/Internal Medicine visit.
- Complementary visits include both clinical visits and visits for complementary tests, which can be carried out outside the center, and will be the following:
- a neuropsychological examination will be performed by a qualified professional.
- Blood tests will be performed to assess the patient's hematologic, biochemical, and coagulation function to determine if the patient meets the eligibility criteria. Blood test must be performed no later than 1 week prior to first TPE treatment and results must be available prior to second visit (Neurology/Internal Medicine) (Eligible/Ineligible) o Ask if patient is fasting. This is a relevant question for the biological samples obtained from the visit. or Hematology
- ESR Erythrocyte sedimentation rate
- Biochemistry o Ferritin o Total protein o Albumin o Globulin o Glycemia o Urea o Creatinine o Sodium o Potassium o Calcium o Chloride o Magnesium o Coagulation o Fibrinogen o Quick Time / Prothrombin Time (PT) o Ketalin Time / Activated Partial Thromboplastin Time ( aPTT) o International Normalized Ratio (INR.
- Immunoglobulin G IgG
- Immunoglobulin A IgA
- Immunoglobulin M IgM
- Anti-thyroid antibodies o Human immunodeficiency virus (HIV) serology o HIV serology Hepatitis C virus (HCV) o Liver enzymes o Aspartate aminotransferase (AST/GOT) o Alanine aminotransferase (ALT/GPT) o Alkaline phosphatase o Gamma-glutamyl transferase (GGT) o Thyroid tests o T3 o T4 o Free T4 o TSH or Urine or sediment
- the patient must present at the Neurology/Internal Medicine visit a radiological report of previous MRI studies. If this is not possible, enter the Neurology/Internal Medicine visit and the Neurology/Internal Medicine visit, will order an MRI of the patient's brain.
- the objective of the prescription phase is to decide whether or not the patient is suitable to receive the AMBAR treatment and, if so, to prepare the patient for the next phase, the application phase.
- the prescription phase includes a second Neurology/Internal Medicine visit (Eligible/Ineligible).
- the prerequisites for the visit are that the patient has already made the first visit by Neurology / Internal Medicine, and also all those complementary visits necessary to confirm the eligibility criteria.
- TPE Application phase - Therapeutic plasma exchange
- TPE therapeutic plasmapheresis
- ESR Erythrocyte sedimentation rate
- Biochemistry o Biochemistry o Total protein o Albumin o Globulin o Glycemia o Urea o Creatinine o Sodium o Potassium o Calcium o Chloride o Magnesium o Coagulation o Fibrinogen o Quick Time / Prothrombin time (PT) o Cephalin time / Activated Partial Thromboplastin Time (aPTT) o International Normalized Ratio (INR) o Immunology o Immunoglobulin G (IgG) o Immunoglobulin A (IgA) o Immunoglobulin M (IgM) o Liver enzymes o Aspartate aminotransferase (AST/GOT) o Alanine aminotransferase (ALT/GPT) o Alkaline phosphatase o Gamma-glutamyl transferase (GGT) o COVID-19 o PGR S
- ECG electrocardiogram
- the internist will perform an evaluation of the patient to determine whether or not the patient can receive the prescribed treatment. To do this, you must:
- Treatment following the AMBAR standard consists of 6 TPE with substitution of 125-150 g of Albutein® 5% or Plasbumin® 5%. It has to be done once a week for 6 weeks. This pattern can be modified at the discretion of the physician.
- the TPE procedure will be performed by the nurse under the supervision of the internist.
- This exploration can be done just before treatment or a maximum of 48 hours before. This exploration consists of:
- Data related to the patient's estimated blood volume calculated by the TPE machine will be collected. In addition, data related to the TPE process will be collected every 30 minutes.
- the end time will be recorded, as well as its duration. It is understood as the time that elapses from the time the patient enters the center until they leave it. It will also be collected whether or not the procedure has been carried out (and the reasons why it has not been carried out).
- the nurse will perform an examination of the patient to verify the patient's condition after receiving the treatment.
- This exploration will consist of:
- ESR Erythrocyte sedimentation rate
- Biochemistry o Biochemistry o Total protein o Albumin o Globulin o Glucose o Urea o Creatinine o Sodium o Potassium o Calcium o Chloride o Magnesium o Coagulation o Fibrinogen o Quick Time / Prothrombin time (PT) o Time of Cephalin / Activated Partial Thromboplastin Time (aPTT) o International Normalized Ratio (INR) o Immunology o Immunoglobulin G (IgG) o Immunoglobulin A (IgA) o Immunoglobulin M (IgM) o Liver enzymes o Aspartate aminotransferase (AST/GOT) o Alanine aminotransferase (ALT/GPT) or Alkaline phosphatase or Gamma-glutamyl transferase (GGT)
- the internist will evaluate the patient at the end of the treatment and will administer the medication, if necessary, until the next visit.
- TPE treatment will continue according to AMBAR standards or as prescribed by the internist.
- TPE follow-up visit a second neurology visit
- the objective of the follow-up phase is to assess the tolerance and efficacy of the treatment in order to decide whether to continue it and move on to the LVPE phase. Likewise, follow-up visits will be used to collect clinical and biological information. of treatment with AMBAR.
- the internist doctor may, at his discretion, request the complementary visits described below to obtain additional information and, finally, a second Neurology/Medicine visit will be carried out to decide on the continuity of the AMBAR treatment.
- a neuropsychological examination will be carried out by a qualified professional.
- ESR Erythrocyte sedimentation rate
- Biochemistry o Biochemistry o Ferritin o Total proteins o Albumin o Globulin o Glycemia o Irea o Creatinine o Sodium o Potassium o Calcium o Chloride o Magnesium o Coagulation o Fibrinogen o Quick Time / Prothrombin Time (PT) o Ketalin Time / Activated Partial Thromboplastin Time (aPTT) o Normalized ratio (INR) o Immunology o Immunoglobulin G (IgG) o Immunoglobulin A (IgA) o Immunoglobulin M (IgM) o Antithyroid antibodies o Human immunodeficiency virus (HIV) serology o Hepatitis C virus (HCV) serology o Liver enzymes o Aspartate aminotransferase (AST/GOT) o Alanine aminotransferase (ALT/GPT) o
- LVPE low volume plasma exchange
- ESR Erythrocyte sedimentation rate
- Biochemistry o Biochemistry o Total protein o Albumin o Globulin o Glucose o Urea o Creatinine o Sodium o Potassium o Calcium o Chloride o Magnesium o Coagulation o Fibrinogen o Quick Time / Prothrombin time (PT) o Time of Cephalin / Activated brownish thromboplastin time (aPTT) o International normalized ratio (INR) o Immunology o Immunoglobulin G (IgG) o Immunoglobulin A (IgA) o Immunoglobulin M (IgM) o Liver enzymes o Aspartate aminotransferase (AST/GOT) o Alanine aminotransferase (ALT/GPT) or Alkaline phosphatase o Gamma-glutamyl transferase (GGT) o COVID-19 o PCR SARS-
- ECG electrocardiogram
- the Internist doctor will perform an evaluation of the patient to determine whether or not the patient can receive the prescribed treatment. To do this, you must:
- the internist will place the peripheral venous line in order to connect the patient to the LVPE machine.
- Treatment following the AMBAR standard consists of 1 LVPE procedure with substitution of 40 g of Albutein® 20% or Plasbumin® 20%. It will be performed once a month during the time prescribed by the internist. This guideline can be modified according to medical criteria. Each procedure will replace between 890 and 880 ml of plasma, depending on the weight of the patient.
- the LVPE procedure will be performed by the nurse under the supervision of the internist.
- Treatment can continue whether the patient is fasting or not. This question is relevant to the biological samples obtained from the visit.
- Data related to the patient's estimated blood volume calculated by the LVPE machine will be collected.
- data related to the LVPE process will be collected every 30 minutes.
- saline may be infused at any time during the procedure.
- the end time will be recorded, as well as its duration. It is understood as the time that elapses from the time the patient enters the center until they leave it. It will also be collected whether or not the procedure has been carried out (and the reasons why it has not been carried out).
- the nurse will perform an examination of the patient to verify the patient's condition after receiving the treatment.
- This exploration will consist of:
- ESR Erythrocyte sedimentation rate
- Biochemistry o Biochemistry o Total protein o Albumin o Globulin o Glucose o Urea o Creatinine o Sodium o Potassium o Calcium o Chloride o Magnesium o Coagulation o Fibrinogen o Quick Time / Prothrombin time (PT) o Time of Catalin / Activated Partial Thromboplastin Time (aPTT) o International Normalized Ratio (INR) o Immunology o Immunoglobulin G (IgG) o Immunoglobulin A (IgA) o Immunoglobulin M (IgM) o Liver enzymes o Aspartate aminotransferase (AST/GOT) o Alanine aminotransferase (ALT/GPT) or Alkaline phosphatase or Gamma-glutamyl transferase (GGT)
- the internist will evaluate the patient at the end of the treatment and will administer the medication, if necessary, until the next visit.
- the internist doctor will prepare the medical report of the LVPE. If the LVPE is number 3 (or if no more than 3 months have passed since the last neurological visit) has not been completed, treatment of the LVPE will continue, according to AMBAR standards or as prescribed by the internist. In the event that LVPE number 3 has been completed (or if more than 3 months have elapsed since the last neurological visit), a second neurology visit (follow-up LVPE visit) will be performed.
- the center will make a control call to the patient, if possible the same day in the afternoon or the next day.
- the objective of the follow-up phase is to evaluate the tolerance and efficacy of the AMBAR medical treatment to decide whether to continue it during the treatment phase.
- LVPE LVPE.
- follow-up visits will be used to collect clinical and biological information on treatment with AMBAR.
- the internist may, at his discretion, request the complementary visits described below to obtain additional information and finally a second Neurology/Medicine visit will be made to decide on the continuity of the AMBAR treatment.
- Follow-up visits during the LVPE phase will take place approximately every 3 months.
- a neuropsychological examination will be carried out by a qualified professional.
- ESR Erythrocyte sedimentation rate
- Biochemistry Albumin o Globulin o Glycemia o Urea o Creatinine o Sodium o Potassium o Calcium o Chloride o Magnesium o Coagulation o Fbrinogen o Quick Time / Prothrombin Time (PT) o Cephalin Time / Activated Pardal Thromboplastin Time (aPTT) o Normalized Ratio (INR) o Immunology o Immunoglobulin G (IgG) o Immunoglobulin A (IgA) o Immunoglobulin M (IgM) o Antithyroid antibodies o Human immunodeficiency virus (HIV) serology o Hepatitis C virus (HCV) serology o Liver enzymes o Aspartate aminotransferase (AST/GOT) o Alanine aminotransferase (ALT/GPT) o Alkaline phosphatase
- Example 1 Safety and effectiveness of therapeutic plasma exchange in combination with low-volume plasma exchange
- the initial mean of the MMSE value (for its acronym in English, Mini Mental State Examination) of this group was 19.0 +/- 5.2 ( 95 CI: 17.4-20.6), while at the end of the treatment the mean was _18.0 + /- 6.2 ( 96 CI: 16.4-19.6), indicating a generalized stabilization considering that Alzheimer's is a highly neurodegenerative disease that usually decreases MMSE values much faster, even reaching 5-6 points per year (Mittal S, Singh J, Pathania M, Goal A (2017) Up in Anns against Alzheimer fe Disease, J Neurol Exp Neural Sci 2017: JNNS-127). A more meticulous observation of this behavior reveals that 34 of the 40 patients (85%) showed an improvement or at least stability in the MMSE value (all variations equal to or less than 3 points are considered stable).
- Table 2 Change in MMSE values of patients under treatment. Patients who showed stabilization or improvement (34 of 40, 85%, 95 % CI: 70.1-94.4%) have been highlighted.
- the total number of therapeutic plasma exchanges (TPE) performed was 240, of which 224 (93.3%, 95 % CI: 89.0-96.0%) were performed without complications.
- the most common adverse effects were very rare: hypotension (4 cases), discomfort (4 cases), syncopal episodes (2 cases), hypogammaglobullnemla (2 cases) and paresthesia (1 case).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Vascular Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22731786.4A EP4331639A1 (en) | 2021-04-30 | 2022-04-28 | Use of therapeutic plasma exchange and low volume plasma exchange for the treatment of a cognitive impairment |
AU2022267051A AU2022267051A1 (en) | 2021-04-30 | 2022-04-28 | Use of therapeutic plasma exchange and low volume plasma exchange for the treatment of a cognitive impairment |
MX2023011872A MX2023011872A (es) | 2021-04-30 | 2022-04-28 | Uso de recambio plasmatico terapeutico y recambio plasmatico de bajo volumen para el tratamiento de un deterioro cognitivo. |
KR1020237035860A KR20240004324A (ko) | 2021-04-30 | 2022-04-28 | 인지 장애의 치료를 위한 치료적 혈장 교환술과 저용량 혈장 교환술의 용도 |
JP2023564196A JP2024516390A (ja) | 2021-04-30 | 2022-04-28 | 認知機能障害を処置するための治療的血漿交換及び低体積血漿交換の使用 |
IL307764A IL307764A (en) | 2021-04-30 | 2022-04-28 | Use of plasma exchange and low volume plasma exchange to treat cognitive impairment |
BR112023020972A BR112023020972A2 (pt) | 2021-04-30 | 2022-04-28 | Uso de troca de plasma terapêutico e baixo volume de troca de plasma para o tratamento de uma diminuição cognitiva |
CN202280029235.6A CN117202949A (zh) | 2021-04-30 | 2022-04-28 | 治疗性血浆置换和低容量血浆置换用于治疗认知损害的用途 |
CA3215030A CA3215030A1 (en) | 2021-04-30 | 2022-04-28 | Use of therapeutic plasma exchange and low volume plasma exchange for the treatment of a cognitive impairment |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21382388.3 | 2021-04-30 | ||
EP21382388 | 2021-04-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022229705A1 true WO2022229705A1 (es) | 2022-11-03 |
Family
ID=75825777
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2022/000246 WO2022229705A1 (es) | 2021-04-30 | 2022-04-28 | Uso de recambio plasmático terapéutico y recambio plasmático de bajo volumen para el tratamiento de un deterioro cognitivo |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP4331639A1 (es) |
JP (1) | JP2024516390A (es) |
KR (1) | KR20240004324A (es) |
CN (1) | CN117202949A (es) |
AR (1) | AR125480A1 (es) |
AU (1) | AU2022267051A1 (es) |
BR (1) | BR112023020972A2 (es) |
CA (1) | CA3215030A1 (es) |
IL (1) | IL307764A (es) |
MX (1) | MX2023011872A (es) |
TW (1) | TW202308682A (es) |
UY (1) | UY39742A (es) |
WO (1) | WO2022229705A1 (es) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090111740A1 (en) * | 2007-10-26 | 2009-04-30 | Grifols, S.A. | Use of therapeutic human albumin for the preparation of a drug for the treatment of patients suffering from cognitive disorders |
EP3643319A1 (en) * | 2018-10-25 | 2020-04-29 | Grifols Worldwide Operations Limited | Use of low volume plasma exchange for the treatment of alzheimer's disease in early and middle stages |
-
2022
- 2022-04-28 WO PCT/IB2022/000246 patent/WO2022229705A1/es active Application Filing
- 2022-04-28 AR ARP220101117A patent/AR125480A1/es unknown
- 2022-04-28 BR BR112023020972A patent/BR112023020972A2/pt unknown
- 2022-04-28 MX MX2023011872A patent/MX2023011872A/es unknown
- 2022-04-28 TW TW111116128A patent/TW202308682A/zh unknown
- 2022-04-28 KR KR1020237035860A patent/KR20240004324A/ko unknown
- 2022-04-28 UY UY0001039742A patent/UY39742A/es unknown
- 2022-04-28 EP EP22731786.4A patent/EP4331639A1/en active Pending
- 2022-04-28 CN CN202280029235.6A patent/CN117202949A/zh active Pending
- 2022-04-28 JP JP2023564196A patent/JP2024516390A/ja active Pending
- 2022-04-28 CA CA3215030A patent/CA3215030A1/en active Pending
- 2022-04-28 AU AU2022267051A patent/AU2022267051A1/en active Pending
- 2022-04-28 IL IL307764A patent/IL307764A/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090111740A1 (en) * | 2007-10-26 | 2009-04-30 | Grifols, S.A. | Use of therapeutic human albumin for the preparation of a drug for the treatment of patients suffering from cognitive disorders |
EP3643319A1 (en) * | 2018-10-25 | 2020-04-29 | Grifols Worldwide Operations Limited | Use of low volume plasma exchange for the treatment of alzheimer's disease in early and middle stages |
Non-Patent Citations (6)
Title |
---|
BOADA ET AL: "Changes in cognitive status of Alzheimer's disease patients treated with plasma exchange and replacement with human albumin plus immunoglobulin. Interim results of the AMBAR trial", ALZHEIMER DEMENTIA,, vol. 12, 1 January 2016 (2016-01-01), pages P419 - P420, XP002790387, DOI: 10.1016/J.JALZ.2016.06.795 * |
BOADA MERCÈ ET AL: "A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study", vol. 16, no. 10, 27 July 2020 (2020-07-27), US, pages 1412 - 1425, XP055846572, ISSN: 1552-5260, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/doi/full-xml/10.1002/alz.12137> DOI: 10.1002/alz.12137 * |
BOADA MERCÈ ET AL: "Plasma exchange for Alzheimer's disease Management by Albumin Replacement (AMBAR) trial: Study design and progress", vol. 5, no. 1, 1 January 2019 (2019-01-01), pages 61 - 69, XP055846366, ISSN: 2352-8737, Retrieved from the Internet <URL:https://dul.usage.elsevier.com/doi/> DOI: 10.1016/j.trci.2019.01.001 * |
COSTA MONTSERRAT ET AL: "Emerging insights into the role of albumin with plasma exchange in Alzheimer's disease management", TRANSFUSION AND APHERESIS SCIENCE, ELSEVIER SCIENCE, LONDON, GB, vol. 60, no. 3, 21 May 2021 (2021-05-21), XP086663376, ISSN: 1473-0502, [retrieved on 20210521], DOI: 10.1016/J.TRANSCI.2021.103164 * |
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 2019, PAEZ A ET AL: "Ambar (Alzheimer's management by albumin replacement) phase 2b/3 trial: Complete clinical, biomarker and neuroimaging results", XP002804340, Database accession no. EMB-631884582 * |
M. BOADA ET AL: "Treatment of Alzheimer disease using combination therapy with plasma exchange and haemapheresis with albumin and intravenous immunoglobulin: Rationale and treatment approach of the AMBAR (Alzheimer Management By Albumin Replacement) study", NEUROLOG?A (ENGLISH EDITION), vol. 31, no. 7, 1 September 2016 (2016-09-01), pages 473 - 481, XP055529120, ISSN: 2173-5808, DOI: 10.1016/j.nrleng.2014.02.009 * |
Also Published As
Publication number | Publication date |
---|---|
TW202308682A (zh) | 2023-03-01 |
AU2022267051A1 (en) | 2023-10-26 |
KR20240004324A (ko) | 2024-01-11 |
BR112023020972A2 (pt) | 2023-12-12 |
JP2024516390A (ja) | 2024-04-15 |
UY39742A (es) | 2022-11-30 |
IL307764A (en) | 2023-12-01 |
AR125480A1 (es) | 2023-07-19 |
EP4331639A1 (en) | 2024-03-06 |
MX2023011872A (es) | 2023-10-17 |
CN117202949A (zh) | 2023-12-08 |
CA3215030A1 (en) | 2022-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Genizi et al. | Kawasaki disease in very young infants: high prevalence of atypical presentation and coronary arteritis | |
Boada et al. | Plasma exchange for Alzheimer's disease Management by Albumin Replacement (AMBAR) trial: Study design and progress | |
Selby et al. | Multiple myeloma treated with high dose intravenous melphalan | |
Devarbhavi et al. | Severe falciparum malaria simulating fulminant hepatic failure | |
Hornik et al. | Central and extrapontine myelinolysis affecting the brain and spinal cord. An unusual presentation of pancreatic encephalopathy | |
Böttiger et al. | Aplastic anaemia: aplastic anaemia and infectious hepatitis | |
WO2022229705A1 (es) | Uso de recambio plasmático terapéutico y recambio plasmático de bajo volumen para el tratamiento de un deterioro cognitivo | |
Seton et al. | Case 18-2008: a 68-year-old man with headache and visual changes after liver transplantation | |
Virk et al. | Avatrombopag for adults with early versus chronic immune thrombocytopenia | |
Shinozaki et al. | A case report of plasmapheresis in the treatment of acute disseminated encephalomyelitis | |
US20240216477A1 (en) | Use of therapeutic plasma exchange and low volume plasma exchange for the treatment of a cognitive impairment | |
Jung et al. | Metformin‐induced encephalopathy without lactic acidosis in a patient with contraindication for metformin | |
Nasr | Glucose-6-phosphate dehydrogenase deficiency with psychosis | |
Matijaca et al. | Neurotoxicity that may mimic progressive multifocal leukoencephalopathy in patient with transplanted kidney | |
Vithana et al. | A Ten‐Year‐Old Boy with Antiepileptic Drugs‐Induced DRESS Syndrome | |
Raut et al. | Plasma Exchange in Refractory Acute Disseminated Encephalomyelitis Associated with COVID-19: Technical Challenges in a Developing Country | |
Hollingsworth et al. | Megaloblastic Anemia of Pregnancy in Two Sisters Case Reports and an Investigation of the Hemolytic Mechanism by Means of Erythrocyte Survival Studies | |
Sacco et al. | Hereditary hemorrhagic telangiectasia: a primer for critical care nurses | |
Groome et al. | Under Pressure | |
Asadzadeh et al. | Hemolytic uremic syndrome following the Aluminum phosphide poisoning: a case report | |
Protocol | Children’s National Medical Center’s transfusion protocol for sickle hemoglobinopathies | |
Maitra et al. | Variable presentations of dengue fever with diagnostic dilemma: A case series | |
Mahajan et al. | Idiopathic pure red cell aplasia: A case series from India | |
Adams | Epidemiology and the Leading Causes of Death | |
Lloyd | Transfusion Medicine and Hemostasis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22731786 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2023/011872 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: AU2022267051 Country of ref document: AU Ref document number: 2022267051 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3215030 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 804388 Country of ref document: NZ Ref document number: 307764 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280029235.6 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023564196 Country of ref document: JP |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023020972 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2022267051 Country of ref document: AU Date of ref document: 20220428 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18557828 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022731786 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2022731786 Country of ref document: EP Effective date: 20231130 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 112023020972 Country of ref document: BR Kind code of ref document: A2 Effective date: 20231009 |